<DOC>
	<DOC>NCT01212133</DOC>
	<brief_summary>This study is conducted in Asia. The aim of this study is to evaluate the safety and effectiveness of liraglutide in subjects with type 2 diabetes mellitus.</brief_summary>
	<brief_title>A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects with type 2 diabetes, including newlydiagnosed patients / those already receiving other antidiabetic medications including GLP1 analogues, who require treatment with liraglutide according to the clinical judgment of their treating physician Subjects who are capable of giving studyspecific signed informed consent before any collection of information Subjects with type 1 diabetes Subjects who are or have previously been on liraglutide Subjects who have previously been enrolled in the study Subjects who are participating in another clinical trial Subjects with a hypersensitivity to liraglutide or to any of the excipients (Disodium phosphate dihydrate, propylene glycol, phenol, water for injections) Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the following 6 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>